Zhou, Qiang
Wang, Zhiqiang
Wang, Heming
Chen, Zhidong
Li, Xiaoyi
Dai, Xiangrong
Zhang, Yong
Yu, Xiaohui
Zhou, Renpeng
Funding for this research was provided by:
the National Major Scientific and Technological Special Project (2020ZX09201014)
Article History
Accepted: 7 December 2022
First Online: 9 January 2023
Declarations
:
: Xiaoyi Li, Xiangrong Dai, Yong Zhang and Xiaohui Yu are employed by Zhaoke Pharmaceutical Co., Ltd, Guangzhou, China. Qiang Zhou, Zhiqiang Wang, Heming Wang, Zhidong Chen, Renpeng Zhou and Wei Hu have no relevant financial or non-financial competing interests to report.
: This study was supported by the National Major Scientific and Technological Special Project (2020ZX09201014). NCT04627116 was sponsored by Lee’s Pharmaceutical Limited.
: Qiang Zhou, Zhiqiang Wang, Renpeng Zhou and Wei Hu contributed to the study conception and design. Renpeng Zhou and Wei Hu performed the clinical trials. Heming Wang, Zhidong Chen, Xiaoyi Li and Xaingrong Dai conducted the biosample analysis. Zhiqiang Wang, Yong Zhang and Xaiohui Yu performed the statistical analysis and interpretation of the data. Qiang Zhou and Zhiqiang Wang drafted the manuscript. All authors were involved in revising the paper critically for intellectual content, and approved the final version to be published.
: This study was approved by the Ethics Committee of the Second Affiliated Hospital of Anhui Medical University (Hefei, China).
: Not applicable.
: Not applicable.
: The data that support the findings of this study are available from the corresponding author (Wei Hu) upon reasonable request.
: Not applicable.